Please check your internet connection and try again.
# زولبيديم (Zolpidem)
## Overview
Zolpidem is a non-benzodiazepine hypnotic agent (Z-drug) that acts as a selective agonist at the GABA-A receptor complex. It has a rapid onset of action and is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
## Primary Indications
- Insomnia (short-term management) characterized by difficulty falling asleep.
## Adult Dosing
- **Immediate-release (IR):** 5 mg (women) or 5–10 mg (men) taken once nightly immediately before bedtime.
- **Extended-release (ER):** 6.25 mg (women) or 12.5 mg (men) taken once nightly.
- **Maximum dose:** 10 mg/day for IR; 12.5 mg/day for ER.
- *Note:* Always prescribe the lowest effective dose.
## Pediatric Dosing
- **Safety/Efficacy:** Not established; use is not recommended in pediatric patients.
## Dose Adjustments
- **Elderly/Debilitated:** Administer 5 mg (IR) or 6.25 mg (ER) maximum to reduce risk of falls and cognitive impairment.
- **Hepatic Impairment:** Mild-to-moderate impairment requires dose reduction (5 mg IR). Avoid use in severe hepatic impairment.
- **Renal Impairment:** No specific adjustment required, though use caution.
## Contraindications
- Known hypersensitivity to zolpidem.
- History of complex sleep behaviors (e.g., sleep-walking, sleep-driving) after taking zolpidem.
## Adverse Effects
- Drowsiness, dizziness, diarrhea, and "drugging" sensation.
- Complex sleep behaviors (e.g., preparing food, making phone calls while asleep).
- Next-day impairment (psychomotor performance).
- Anterograde amnesia.
## Key Drug Interactions
- **CNS Depressants:** Addition of alcohol, opioids, or benzodiazepines increases risk of severe sedation, respiratory depression, and death.
- **CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin):** May significantly increase zolpidem levels; avoid or adjust dose.
- **CYP3A4 Inducers (e.g., rifampin):** May decrease efficacy.
## Monitoring
- Assess for next-day impairment, especially when dose is escalated.
- Monitor for signs of parasomnias or suicidal ideation.
- Evaluate the need for continued therapy after 7–10 days of use.
## Clinical Pearls
- **Administration:** Should only be taken if the patient has a full 7–8 hours available for sleep.
- **Sublingual/Oral Spray:** Ensure patients understand specific administration instructions (e.g., "Intermezzo" is specifically for middle-of-the-night awakening if at least 4 hours of bedtime remain).
- **Tolerance:** Tolerance and physical dependence may occur with prolonged use; taper if stopping after chronic use to avoid withdrawal.
- **Depression:** Use caution in patients with depression, as sedative-hypnotics may worsen symptoms.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and FDA-approved labeling before administering medication.*
